ViewRay Stock Forecast, Price & News

+0.01 (+0.17 %)
(As of 06/14/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume59,314 shs
Average Volume979,884 shs
Market Capitalization$941.33 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

ViewRay logo

About ViewRay

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.29 out of 5 stars

Medical Sector

870th out of 2,100 stocks

Electromedical Equipment Industry

22nd out of 62 stocks

Analyst Opinion: 1.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ViewRay (NASDAQ:VRAY) Frequently Asked Questions

Is ViewRay a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ViewRay stock.
View analyst ratings for ViewRay
or view top-rated stocks.

What stocks does MarketBeat like better than ViewRay?

Wall Street analysts have given ViewRay a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ViewRay wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ViewRay's next earnings date?

ViewRay is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for ViewRay

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) posted its quarterly earnings results on Thursday, May, 6th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.01. ViewRay had a negative trailing twelve-month return on equity of 69.14% and a negative net margin of 183.76%.
View ViewRay's earnings history

How has ViewRay's stock been impacted by COVID-19?

ViewRay's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VRAY shares have increased by 243.2% and is now trading at $5.80.
View which stocks have been most impacted by COVID-19

What price target have analysts set for VRAY?

7 equities research analysts have issued 1 year price targets for ViewRay's stock. Their forecasts range from $3.00 to $7.00. On average, they anticipate ViewRay's share price to reach $4.86 in the next twelve months. This suggests that the stock has a possible downside of 16.3%.
View analysts' price targets for ViewRay
or view top-rated stocks among Wall Street analysts.

Who are ViewRay's key executives?

ViewRay's management team includes the following people:
  • Mr. Scott William Drake, Pres, CEO & Director (Age 53, Pay $1.23M)
  • Dr. James F. Dempsey, Chief Scientific Officer (Age 50, Pay $468.31k)
  • Mr. Zachary William Stassen, Chief Financial Officer (Age 42)
  • Ms. Ashley Kluth, Sr. Mang. of Investor Relations
  • Mr. Robert S. McCormack, Sr. VP, Gen. Counsel & Corp. Sec.
  • Karen Hackstaff, VP of Marketing
  • Mr. Robert Michael Fuchs, Chief HR Officer (Age 54)
  • Dr. Martin Fuss, Chief Medical Officer

What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay CEO Scott Drake on Scott Drake has an approval rating of 59% among ViewRay's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ViewRay's key competitors?

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

When did ViewRay IPO?

(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Who are ViewRay's major shareholders?

ViewRay's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (12.82%), Hudson Executive Capital LP (9.13%), Pura Vida Investments LLC (5.96%), BlackRock Inc. (5.94%), Bamco Inc. NY (1.98%) and Tamarack Advisers LP (1.51%). Company insiders that own ViewRay stock include International Ltd Fosun, James F Dempsey, Scott William Drake and Shahriar Matin.
View institutional ownership trends for ViewRay

Which major investors are selling ViewRay stock?

VRAY stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Millennium Management LLC, Goldman Sachs Group Inc., Royce & Associates LP, Credit Suisse AG, Kahn Brothers Group Inc. DE, and Hodges Capital Management Inc..
View insider buying and selling activity for ViewRay
or view top insider-selling stocks.

Which major investors are buying ViewRay stock?

VRAY stock was bought by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Artisan Partners Limited Partnership, Pura Vida Investments LLC, Hudson Executive Capital LP, BlackRock Inc., Bamco Inc. NY, Point72 Asset Management L.P., and Dimensional Fund Advisors LP. Company insiders that have bought ViewRay stock in the last two years include Scott William Drake, and Shahriar Matin.
View insider buying and selling activity for ViewRay
or or view top insider-buying stocks.

How do I buy shares of ViewRay?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ViewRay's stock price today?

One share of VRAY stock can currently be purchased for approximately $5.80.

How much money does ViewRay make?

ViewRay has a market capitalization of $938.09 million and generates $57.02 million in revenue each year. The company earns $-107,910,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.

How many employees does ViewRay have?

ViewRay employs 236 workers across the globe.

What is ViewRay's official website?

The official website for ViewRay is

Where are ViewRay's headquarters?

ViewRay is headquartered at 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146.

How can I contact ViewRay?

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.